Centene (CNC) AI Stock Analysis

• Market Cap: $19.15B
• Dividend Yield: N/A
• Average Volume (3M): 7.87M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: 14.92%
• EPS Growth: -286.72%
• Country: US
• Employees: 60,400
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Healthcare Plans
• EPS (TTM): 0.50
• Shares Outstanding: 491,518,000
• 10 Day Avg. Volume: 6,446,422
• 30 Day Avg. Volume: 7,866,574
• PEG Ratio: 0.35
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 0.19
• P/FCF Ratio: -64.51
• Enterprise Value/Market Cap: 1.84
• Enterprise Value/Revenue: 0.19
• Enterprise Value/Gross Profit: 1.76
• Enterprise Value/Ebitda: -12.16
• 1Y Price Target: $39.92
• Price Target Upside: 2.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15
• EPS Forecast (FY): 2
• Revenue Forecast (FY): $193.57B

• Rating: 58 Neutral
• Price Target: $41.00 ▲(5.21% Upside)

Centene's overall stock score reflects a mixed financial performance with significant profitability challenges. Technical analysis indicates short-term bullish momentum, but valuation concerns persist due to a negative P/E ratio. The earnings call provided some optimism with improved EPS guidance, yet highlighted ongoing operational pressures.

Centene Business Overview & Revenue Model

Company Description

Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.

How the Company Makes Money

Centene generates revenue primarily through its health insurance plans, where it receives government funding for providing healthcare services to members enrolled in Medicaid and Medicare programs. The company operates on a capitation model, where it is paid a fixed amount per member per month (PMPM) by state and federal government programs to cover the health services for its members. Key revenue streams include premium revenue from Medicaid and Medicare, and supplemental services such as pharmacy benefits management. Additionally, Centene has formed strategic partnerships and collaborations with other healthcare providers and organizations, enhancing its service offerings and expanding its market reach, which contributes significantly to its overall earnings.

Centene Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Centene Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 38.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNC, the sentiment is Neutral. The current price of 38.97 is above the 20-day moving average (MA) of 38.54, above the 50-day MA of 36.94, and below the 200-day MA of 43.66, indicating a neutral trend. The MACD of 0.84 indicates Positive momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 48.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CNC.

Centene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
ELV	76 Outperform	$78.21B	14.39	12.61%	1.94%	11.96%	-11.11%
CI	72 Outperform	$73.76B	12.18	14.65%	2.19%	16.75%	113.48%
MOH	71 Outperform	$8.27B	10.06	19.71%	―	13.71%	-18.02%
HUM	69 Neutral	$31.05B	24.20	7.15%	1.37%	9.87%	-5.58%
CNC	58 Neutral	$19.15B	-3.59	-21.93%	―	14.92%	-286.72%
OSCR	49 Neutral	$4.16B	-13.68	-22.32%	―	37.38%	-912.18%

Centene Corporate Events

Centene to Present at UBS 2025 Healthcare Conference

Centene Corporation announced its participation in the UBS 2025 Global Healthcare Conference on November 11, 2025, where it will discuss its financial outlook. The company maintains its forecast of a diluted loss per share not exceeding $(12.85) and an adjusted diluted EPS of at least $2.00 for the full year 2025. Centene emphasizes the use of non-GAAP financial measures to provide a clearer understanding of its core performance, excluding certain expenses and amortizations, to better assess its ongoing operations and performance consistency.

Centene to Present at Deutsche Bank Healthcare Summit

Centene Corporation announced its participation in the Deutsche Bank 2025 Healthcare Summit on September 11, 2025, where management will discuss the company’s business and financial results through August. The results align with its full-year 2025 forecast of approximately $1.75 adjusted diluted earnings per share. The company emphasizes the use of non-GAAP financial measures to provide investors with a clearer view of its core operations, although it cautions that these measures may differ from those used by other companies.